UroGen Pharma Ltd
URGN
40.70
-0.73
-1.76%
UroGen Pharma Ltd
US · URGN
#2773 by market cap
Listed 2017
40.70
-0.73
-1.76%
Live - 5344 symbols - heartbeat 490s ago
· 2026-10-08 05:49
Pre-market
40.90
+0.49%
After-hours
40.50
-0.49%
- Market cap
- 1.99B
- P/E (TTM)i
- -20.66
- P/Bi
- -15.02
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on URGN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.2 percentage points.
Institutional ownership
- Held by institutions
- 96.01% -1.20pp
- Institutions
- 225 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund32.05%
Mutual Fund29.70%
Public Company19.53%
VC/PE Fund9.19%
Private Company4.42%
Individual/Insider1.90%
Government Pension Fund1.08%
Other2.09%
Top holders as of 2026-06-30
RTW Investments, LP
9.30% · 4.54M sh
The Toronto-Dominion Bank
6.90% · 3.37M sh
BlackRock
6.55% · 3.20M sh
Morgan Stanley
5.24% · 2.56M sh
Kynam Capital Management, LP
4.98% · 2.43M sh
Jefferies Financial Group Inc.
4.50% · 2.20M sh
SG Americas Securities, LLC
4.20% · 2.05M sh
American Century Investment Management
3.45% · 1.69M sh
Acorn Bioventures
3.42% · 1.67M sh
Point72 Asset Management, L.P.
3.12% · 1.53M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| Arie Belldegrun | Independent Chairperson | 0.84% |
| Elizabeth Barrett | Chief Executive Officer | 0.67% |
| Mark Schoenberg | Chief Medical Officer | 0.12% |
| Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | 0.11% |
| Dong Kim | Chief Financial Officer | 0.09% |
| Fred Cohen | Independent Director | 0.03% |
| James Robinson | Director | 0.02% |
| Christopher Degnan | Chief Financial Officer | 0.00% |
| Daniel Wildman | Independent Director | 0.00% |
| Cynthia Butitta | Independent Director | 0.00% |
| Leana Wen | Independent Director | 0.00% |
| Stuart Holden | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Sale | -871 | $42.92 |
| 2026-09-07 | Mark Schoenberg | Chief Medical Officer | Intent to Sell (Form 144) | -871 | $44.09 |
| 2026-09-07 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Sale | -1,519 | $42.54 |
| 2026-09-07 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Intent to Sell (Form 144) | -1,519 | $44.09 |
| 2026-09-06 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Retained | +796 | -- |
| 2026-09-06 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Retained | +1,815 | -- |
| 2026-08-25 | James Robinson | Director | Derivative Exercise and Retained | +2,000 | -- |
| 2026-08-19 | Mark Schoenberg | Chief Medical Officer | Open Market Disposition | -60,677 | $47.05 |
| 2026-07-08 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $40.00 |
| 2026-06-21 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 |
| 2026-06-21 | Stuart Holden | Independent Director | Other Derivative Acquisition | +20,000 | $34.99 |
| 2026-06-21 | Arie Belldegrun | Independent Chairperson | Other Derivative Acquisition | +20,000 | $34.99 |
| 2026-06-21 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 |
| 2026-06-21 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $35.01 |
| 2026-06-21 | James Robinson | Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | James Robinson | Director | Other Derivative Acquisition | +10,000 | $34.99 |
| 2026-06-21 | Leana Wen | Independent Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | Leana Wen | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:49:07 · For reference only, not investment advice and not tailored to your situation.